Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE787.051.8 (+0.23 % )
PREV CLOSE (Rs.) 785.25
OPEN PRICE (Rs.) 787.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 787.05 (38 )
VOLUME 81172
TODAY'S LOW / HIGH (Rs.)779.00 791.35
52 WK LOW / HIGH (Rs.)527.05 830
NSE788.30 1.75 (+0.22 % )
PREV CLOSE(Rs.) 786.55
OPEN PRICE (Rs.) 784.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 788.30 (59 )
VOLUME 1884849
TODAY'S LOW / HIGH(Rs.) 779.00 791.60
52 WK LOW / HIGH (Rs.)527 830.45

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 637.67
Dividend Yield(%) 0.32
TTM EPS (Rs.) 23.19
P/E Ratio 33.94
Book Value (Rs.) 180.71
Face Value (Rs.) 1
MCap (Rs. in Mn) 461138.58
Price/Earning (TTM) 26.58
Price/Sales (TTM) 4.39
Price/Book (MRQ) 4.36
PAT Margin (%) 17.59
ROCE (%) 19.02
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
07Jan01-07-2019$Aurobindo Pharma informs about investor conference Aurobindo Pharma informs abo

Aurobindo Pharma has informed that the company is participating in the 37th Annual JP Morgan Healthcare Conference being held in San Francisco and California from 7th to 10th January, 2019. The attached presentation will be used in the aforesaid investor conference. The presentation is also being uploaded on the website of the company- https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma has informed that the company is participating..
02Jan01-02-2019$Aurobindo Pharma’s arm recalls 80 lots of blood pressure drug from America Aurobindo Pharma’s arm rec

Aurobindo Pharma’s subsidiary -- Aurobindo Pharma USA Inc is recalling 80 lots of tablets used for treatment of high blood pressure and heart failure from the American market which include Amlodipine Valsartan tablets USP, Valsartan HCTZ tablets USP and Valsartan tablets USP. This is done due to presence of impurity found in the finished drug product that may cause cancer in humans. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma’s subsidiary -- Aurobindo Pharma USA Inc is..
28Dec12-28-2018$Lemon Tree Hotels, Kansai Nerolac Paints and Karnataka Bank to see some action today Lemon Tree Hotels, Kansai Ne

Lemon Tree Hotels has formed a Joint Venture (JV) with an affiliate of Warburg Pincus, a leading global private equity firm focused on growth investing, to create a co-living platform. The JV marks Lemon Tree Hotel's entry into an adjacent but new business segment focusing on the development of institutional-grade rental housing accommodation serving both students and young working professionals across major educational clusters and key office markets in India.

Kansai Nerolac Paints has entered into Share Purchase Agreement (SPA) to acquire 100% equity stake in Perma Construction Aids as on the Closing Date for a total consideration of Rs 29.10 crore. The company is expanding its product portfolio in construction chemicals. The acquisition of Perma Construction Aids will increase its product offerings in construction chemicals business.

Karnataka Bank has opened its 829th Branch at Bengaluru - Heggadadevanapura Alur GP on December 27, 2018. Earlier, the Bank has inaugurated its 825th branch at Mangaluru - Kavoor, 826th branch at Kadabagere and 827th branch at Ele Kodigehalli in the state of Karnataka.

Phoenix Township’s board has approved proposal to enter a Memorandum of Understanding (MOU) with Castle House Goa Situated Patnem Paloem Road, Palolem, Canaona, Goa, to takeover the business of the Castle House Hotel, In view to expansion of the business of the company in Goa region. The Board of the company at its meeting held on December 27, 2018, approved the same.

Indian Oil Corporation (IOC) may quit its plan to buy 50% stake in the Mundra LNG terminal in Gujarat, according to a report. Earlier, in August 2017, the company has received an in-principle approval from its board to acquire 50% stake in the 5 million tonnes per annum terminal (mtpa) for around Rs 750 crore.

Selan Exploration Technology has received its board approval for buyback of equity shares at a price not exceeding Rs 300 per share. The company will aggregate an amount of Rs 25 crore from the open market through stock exchange mechanism.

Aurobindo Pharma’s injectable business unit -- AuroMedics has achieved a topline of $50 million in Q2 FY19, a growth of 8% as compared to corresponding quarter previous year. The company has filed a total of 104 injectables, abbreviated new drug applications (ANDAs), out of which 59 have received final approval and one tentative approval.

Lemon Tree Hotels has formed a Joint Venture (JV) with an affil..
27Dec12-27-2018$Aurobindo Pharma’s injectable business achieves $50 million revenue in Q2 Aurobindo Pharma’s injecta

Aurobindo Pharma’s injectable business unit -- AuroMedics has achieved a topline of $50 million in Q2 FY19, a growth of 8% as compared to corresponding quarter previous year. The company has filed a total of 104 injectables, abbreviated new drug applications (ANDAs), out of which 59 have received final approval and one tentative approval.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma’s injectable business unit -- AuroMedics has..
24Dec12-24-2018$Aurobindo Pharma receives USFDA nod for Vecuronium Bromide Injection Aurobindo Pharma receives US

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg. Aurobindo’s Vecuronium Bromide Injection is a generic equivalent of Organon’s Norcuron Injection. The product will be launched in Q4FY19.

Vecuronium Bromide Injection is used as part of general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is also used to facilitate endotracheal intubation. The approved product has an estimated market size of $11 million for the twelve months ending September 2018 according to IQVIA.

This is the 58th ANDA to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing general injectable & ophthalmic products. The company now has a total of 397 ANDA approvals (369 Final approvals including 20 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has received final approval from the US Food &..
Financials More
Rs. in Millions
QTR Sep 18 ANNUAL 18
Net Profit3809.518127.7
Gross Profit 4794.1 23429.4
Operating Profit 6111.527506.6
Net Sales 31703.9103031.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 6366.20 (2.22%)
M.Cap ( in Cr)
14661.75
Eris Lifesciences (BSE)
 709.15 (9.96%)
M.Cap ( in Cr)
9752.06
Torrent Pharma (BSE)
 1945.25 (2.84%)
M.Cap ( in Cr)
32918.05
Dr. Reddys Lab (BSE)
 2621.85 (1.15%)
M.Cap ( in Cr)
43538.67
Piramal Enterprises (BSE)
 2367.35 (0.99%)
M.Cap ( in Cr)
43420.10
Shareholding Pattern More
PROMOTERS 51.87 %
MUTUAL FUNDS/UTI 14.13 %
NON-INSTITUTION 13.62 %
FI/BANKS/INSURANCE 0.31 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested